Equities researchers at Robert W. Baird began coverage on shares of Myovant Sciences Ltd (NASDAQ:MYOV) in a report released on Monday. The brokerage set an “outperform” rating and a $20.00 price target on the stock. Robert W. Baird’s price target would suggest a potential upside of 81.32% from the stock’s current price.

Analyst Recommendations for Myovant Sciences (NASDAQ:MYOV)

Shares of Myovant Sciences (NASDAQ:MYOV) opened at 11.03 on Monday. The firm’s market capitalization is $480.80 million. The firm’s 50-day moving average price is $11.40 and its 200-day moving average price is $11.40. Myovant Sciences has a 12 month low of $10.26 and a 12 month high of $13.31.

ILLEGAL ACTIVITY NOTICE: This piece of content was reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this piece of content on another website, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright law. The correct version of this piece of content can be viewed at https://www.thecerbatgem.com/2016/11/23/myovant-sciences-ltd-myov-now-covered-by-robert-w-baird.html.

Myovant Sciences Company Profile

Myovant Sciences Ltd. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for women’s health diseases and other endocrine-related disorders. Its main product candidate is Relugolix. Relugolix is an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone (GnRH) receptor antagonist that binds to and inhibits receptors in the anterior pituitary gland.

5 Day Chart for NASDAQ:MYOV

Receive News & Stock Ratings for Myovant Sciences Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myovant Sciences Ltd and related stocks with our FREE daily email newsletter.